TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab.

Autor: Isoda, Bunpei1 (AUTHOR) bunpeiisoda@gmail.com, Kandori, Shuya1 (AUTHOR) n.satoshi19880320@gmail.com, Sazuka, Tomokazu2 (AUTHOR) tomo1ata2@yahoo.co.jp, Kojima, Takahiro3 (AUTHOR) t.kojima@aichi-cc.jp, Nitta, Satoshi1 (AUTHOR) baseball4420002001@yahoo.co.jp, Shiga, Masanobu1 (AUTHOR) nagumoyoshiyuki@gmail.com, Nagumo, Yoshiyuki1 (AUTHOR) nishiuro@md.tsukuba.ac.jp, Fujimoto, Ayumi2 (AUTHOR) ayuroom@gmail.com, Arai, Takayuki2 (AUTHOR) takataka50423@gmail.com, Sato, Hiroaki2 (AUTHOR) hhiirrooaakkii14@yahoo.co.jp, Mathis, Bryan J.4 (AUTHOR) bmathis@md.tsukuba.ac.jp, Wu, Chia-Ling5 (AUTHOR) jalinwu@actgenomics.com, Jan, Yi-Hua5 (AUTHOR) isaacjan@actgenomics.com, Ichikawa, Tomohiko2 (AUTHOR) tomohiko_ichikawa@faculty.chiba-u.jp, Nishiyama, Hiroyuki1 (AUTHOR)
Zdroj: International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 13, p7444. 15p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje